EANS-News: Marseille-Kliniken AG / Resolutions of extraordinary general meeting support the strategic reorientation of Marseille-Kliniken AG

Hamburg, Germany (euro adhoc) -

Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

19 October 2012 - The extraordinary general
meeting of Marseille-Kliniken AG held today at its headquarter in Hamburg approved all applications introduced by the company's administration with a majority of more than 99 percent. The attending shareholders represented more than 67 percent of the share capital.

With the approved shift from Regulated Market (Prime Standard) to Entry Standard as part of the Open Market at the Frankfurt Stock Exchange, Marseille-Kliniken AG consistently resumes its strategic reorientation and internal reorganization. The change reflects the company's recent development, as it owns a much leaner competitive position after the business segments rehabilitation and acute care have been disinvested or abandoned according to plan. Therefore the Entry Standard appears to be the appropriate listing segment. The principal stock market listing in Frankfurt and the respective trading hours will however remain unchanged.

The company's streamlining is furthermore represented by an approved amendment of the statutes for a future reduction of the supervisory board from previously six to than three members. In this context following the extraordinary general meeting today Messrs Uwe Bergheim and Prof. Dr. med. Matthias P. Schönermark have already announced their intention to resign from office after the end of the annual general meeting which is planned for 3 December 2012. Another amendment of the statutes builds furthermore the basis for a future adjustment and new regulation of the compensation for the members of the supervisory board.

Michael Thanheiser, chairman of Marseille-Kliniken AG, comments on the resolutions of the extraordinary general meeting as follows: "We wanted to give our shareholders the possibility to decide for their own about the adequate listing segment. The clear vote for the shift to Entry Standard is consistent with our company's recent development, as our strategic reorientation aims at streamlining the business and realising increases in efficiency. The same applies for the reduction of the supervisory board. Both resolutions of our shareholders are therefore also a confirmation of our corporate strategy."

-- End of Corporate News ---

About Marseille-Kliniken AG:

Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57 residential care facilities, three residential units for assisted living and about 4,700 employees is a market leading listed company on health care in Germany. The business model is significantly influenced by the demographic development. Therefore Marseille-Kliniken AG has a secured future. Short-term economic fluctuations on the other hand exert only a minor influence. As a consistently modern company with strong focus on quality, the private enterprise is in a good position within a competitive environment primarily characterized by regionally active charities.

end of announcement euro adhoc

company: Marseille-Kliniken AG Alte Jakobstraße 79/80 D-10179 Berlin phone: +49 (0)30 246 32-400 FAX: +49 (0)30 246 32-401 mail: info@marseille-kliniken.de WWW: http://www.marseille-kliniken.de sector: Pharmaceuticals ISIN: DE0007783003 indexes: CDAX, Classic All Share, Prime All Share

stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_7994/aom

Rückfragen & Kontakt:

Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Tel.: +49-(0)40 / 3202791-0